Taibang Biologic Group is a leading fully integrated plasma-based biopharmaceutical company in China. The company’s core capabilities include plasma collection, and the manufacturing and commercialization of human plasma-based biopharmaceutical products. These products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. As the company focuses on its plasma business, Taibang have expanded its product pipeline to include non-plasma biopharmaceutical products and bio-medical device products to complement its market position and expand its base of users in the growing core plasma therapeutic business.
Location: China
Investors 2
| Date | Name | Website |
| - | Centurium ... | centurium.... |
| - | IDG Capita... | en.idgcapi... |
Mentions in press and media 2
| Date | Title | Description |
| 20.04.2021 | CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. China Biologic Products : Announces Completion of Going Private Transaction | BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announce... |
| 04.06.2016 | China Biologic announces secondary offering of common stock; Warburg Pincus makes partial exit | Premium US-based private equity Warburg Pincus agreed to sell 2.775 million common shares in China Biologic Products Inc (CBPO), one of the top three producers of plasma products in China, in an underwritten public offering, according to th... |